These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
671 related items for PubMed ID: 30169321
1. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. Plazzi G, Ruoff C, Lecendreux M, Dauvilliers Y, Rosen CL, Black J, Parvataneni R, Guinta D, Wang YG, Mignot E. Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321 [Abstract] [Full Text] [Related]
2. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy. Bogan RK, Foldvary-Schaefer N, Skowronski R, Chen A, Thorpy MJ. CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322 [Abstract] [Full Text] [Related]
3. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, Morse AM, Šonka K, Thorpy MJ, Mignot E, Chandler P, Parvataneni R, Black J, Sterkel A, Chen D, Skobieranda F, Bogan RK. Lancet Neurol; 2022 Jan; 21(1):53-65. PubMed ID: 34942138 [Abstract] [Full Text] [Related]
8. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC, HARMONY-CTP study group. Lancet Neurol; 2017 Mar; 16(3):200-207. PubMed ID: 28129985 [Abstract] [Full Text] [Related]
9. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. Xyrem International Study Group. J Clin Sleep Med; 2005 Oct 15; 1(4):391-7. PubMed ID: 17564408 [Abstract] [Full Text] [Related]
10. Effect of sodium oxybate on body mass index in pediatric patients with narcolepsy. Dauvilliers Y, Lammers GJ, Lecendreux M, Maski K, Kansagra S, Black J, Parvataneni R, Chen A, Wang YG, Plazzi G. J Clin Sleep Med; 2024 Mar 01; 20(3):445-454. PubMed ID: 37942930 [Abstract] [Full Text] [Related]
12. Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients. Prescrire Int; 2007 Jun 01; 16(89):98-101. PubMed ID: 17582923 [Abstract] [Full Text] [Related]
14. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. U.S. Xyrem Multicenter Study Group. Sleep Med; 2004 Mar 01; 5(2):119-23. PubMed ID: 15033130 [Abstract] [Full Text] [Related]
17. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. Bogan RK, Roth T, Schwartz J, Miloslavsky M. J Clin Sleep Med; 2015 Apr 15; 11(4):427-32. PubMed ID: 25580605 [Abstract] [Full Text] [Related]